BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
USA - English
Share this article
JERUSALEM, May 13, 2021 /PRNewswire/
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today published its fourth quarter and full year financial results for the year ended December 31, 2020 and provided a business update.
Fourth Quarter 2020 Financial Summary
Results are in New Israel Shekels (NIS) and convenience translation to US$ is provided using the exchange rate of 3.215 (NIS/US$), the rate as of the close of business on December 31, 2020.
(2)
INDIANAPOLIS (dpa-AFX) - Today s Daily Dose brings you news about the effectiveness of Lilly s Bamlanivimab in reducing the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, executive changes at BiondVax Pharma, regulatory update on Genetic Technologies COVID-19 PRS Test, Adamis SYMJEPI products being made available in the Walgreens Prescription Savings Club, Fluidigm s Advanta Dx SARS-CoV-2 RT-PCR Assay receiving the CE-IVD mark.
Read on.
1. Adamis to Offer SYMJEPI in Walgreens Prescription Savings Club
Adamis Pharmaceuticals Corporation (ADMP) surged more than 90% in after-hours Thursday, on news of its SYMJEPI products now being available to members of the Walgreens Prescription Savings Club program.